By: IPP Bureau
Last updated : June 08, 2021 11:19 am
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
Dr. Reddy’s Laboratories Ltd. along with its subsidiaries announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) has been approved by the U.S. Food and Drug Administration (USFDA).
“We are pleased to bring this important product to market at this time,” says Marc Kikuchi, CEO - North America Generics, Dr. Reddy’s Laboratories.
“We’re excited to extend our strategic partnership with Gland Pharma whose hard work, in collaboration with the team at Dr. Reddy’s, has enabled the execution of this launch,” added Kikuchi.
"We are delighted about this collaboration, as it brings together Dr. Reddy’s experienced marketing and distribution capabilities and Gland Pharma’s robust development and manufacturing capabilities. Gland Pharma has an exclusive API supply arrangement for this product and a dedicated manufacturing facility in Hyderabad for Ertapenem Injection. With the launch of this product we see increased capacity utilization of this dedicated Penem facility,” says Srinivas Sadu, MD and CEO, Gland Pharma Ltd.
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health.
Dr. Reddy’s Ertapenem for Injection, 1 g/vial, is available in packs of 10 vials per carton.